References
- Zawilska JB. “Legal highs” – new players in the old drama. Curr Drug Abuse Rev 2011; 4:122–130.
- Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K. CP47,497-C8 and JWH073, commonly found in ‘Spice’ herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 2011; 659:139–145.
- Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, . Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoylsubstituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem 2005; 13:89–112.
- Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 2009; 60:25566.
- Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, . Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 2010; 67:974–982. Epub 2009 Nov 22.
- Ortega-Alvaro A, Aracil-Fernández A, García-Gutiérrez MS, Navarrete F, Manzanares J. Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 2011; 36:1489–1504. Epub 2011 Mar 23.
- Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 2007; 194:505–515.
- Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoids agonists: a case series. Am J Psychiatry 2011; 168:1119.
- Meltzer PC, Butler D, Deschamps JR, Madras BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 2006; 49:1420–1432.
- Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011; 49:499–505.
- Smollin C, Murray S, Gerona R. An unexpected finding of MDPPP in a patient with severe agitation and hallucinations. [Abstract]. Clin Toxicol 2011; 49:515–627.
- Libiseller K, Pavlic M, Grubwieser P, Rabl W. An announced suicide with ecstasy. Int J Legal Med 2007; 121:40–43.
- Van der Veer N, Friday J. Persistent psychosis following the use of Spice. Schizophr Res 2011; 130:285–286.
- Vaiva G, Boss V, Bailly D, Thomas P, Lestavel P, Goudemand M. An “accidental” acute psychosis with ecstasy use. J Psychoactive Drugs. 2001; 33:95–98.
- Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 2012; 36:360–371.